Aurinia Pharmaceuticals Inc (AUPH)

[Zeppo]

Where Gensight is very close to having a marketable product (it's already being used for a few special situations), APTO is redoing a Phase 1 a/b test for acute leukemia conditions. The reason for the repeat performance is that the product, evidently, is safe and effective at more than one dosage level (a good spot to be in). So it's running a new test with increased dosage. I lost a 47 year old first cousin to acute leukemia in 1998, so this one really got my attention.